– USA, CA – Cesca Therapeutics Inc. (Nasdaq:KOOL), an autologous cell-based regenerative medicine company, announced today the appointment of Robin C. Stracey as Chief Executive Officer.
Robin C. Stracey, (57) was appointed to the Board of Directors of Cesca Therapeutics in July 2011 and will remain a member of the Board. On October 29, 2014, the Company announced that Mr. Stracey had been appointed to serve as Interim CEO. Mr. Stracey had previously served as the President and Chief Executive Officer at several companies, both public and private, and has over thirty years of experience in the global life sciences business.
Craig W. Moore, Chairman of Cesca Therapeutics’ Board of Directors commented, “The Board of Directors felt very comfortable appointing Robin as Interim CEO in October of last year. During the past seven months, he has guided Cesca through several challenges, without the Company losing focus on its breakthrough clinical programs. We are delighted that he has agreed to assume the permanent role of Chief Executive Officer.”
Robin C. Stracey added, “This is an exciting time for the Company and I am thrilled to be involved on a full-time and permanent basis. I look forward to working with the talented employees at Cesca during the next phase of the Company’s growth and development. I appreciate very much the support I have received so far from both the Board of Directors and the entire Cesca team.”
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. is engaged in the research, development and commercialization of autologous cell-based therapeutics for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapy products. These include:
SurgWerks; proprietary stem cell therapy point-of-care kits for the treatment of vascular and orthopedic indications that integrate the following indication specific elements:
Cell harvesting
Cell processing and selection
Cell diagnostics
Cell delivery
CellWerksTM; a proprietary stem cell laboratory kit for the processing of target cells used in the treatment of oncological and hematological disorders.
The AutoXpress (AXP); a proprietary automated device, along with companion sterile blood processing disposables, for the harvesting of stem cells from cord blood.
The MarrowXpress (MXP); a derivative product of the AXP and its accompanying disposable bag set, for the isolation and concentration of stem cells from bone marrow. Self-powered and microprocessor-controlled, the MXP contains flow control optical sensors that volume-reduces blood from bone marrow to a user defined volume in 30 minutes while retaining over 90% of mononuclear cells (MNCs).
The Res-Q 60 (Res-Q); a point-of-care system designed for the preparation of cell concentrates, including stem cells, from bone marrow aspirates and whole blood for platelet rich plasma (PRP).
The BioArchive System; an automated cryogenic device, used by cord blood stem cell banks in more than 30 countries, for cryopreservation and archiving of cord blood stem cell units for transplant.
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
